Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2026)

Vir Biotechnology has reported Cash from Financing Activities for 9 years, with the latest figure at $162.5 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 27077.76% year-over-year to $162.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.7 million (up 3328.01% YoY) and the FY2025 annual result came in at $3.8 million, down 13.74% from the prior year.
• Cash from Financing Activities advanced to $162.5 million in Q1 2026 per VIR's latest filing, from $1.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $162.5 million in Q1 2026 and troughed at $31000.0 in Q3 2024.
• A 5-year average of $12.5 million and a median of $2.0 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities sank 93.52% in 2024, then surged 27077.76% in 2026.
• Over 5 years, Cash from Financing Activities stood at $2.0 million in 2022, then declined by 16.46% to $1.7 million in 2023, then fell by 24.82% to $1.3 million in 2024, then dropped by 17.74% to $1.0 million in 2025, then surged by 15542.25% to $162.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $162.5 million, $1.0 million, and $102000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.